May 11, 2017

Power of Research Not Lost on Graduates of Patient Scientist Academy

Learning how research is done at UAMS and how they can be a part of it was an eye-opener for the nine new graduates of the Translational Research Institute’s inaugural UAMS Patient Scientist Academy. Over four two-hour sessions in April, the academy covered research basics such as the difference between blind and double-blind trials, research…

Fire Alarm Disrupts, Does Not Deter TRI ‘A-Team’

Homer Paul, a research participant, was in the midst of a 10-hour series of blood draws and neurological tests for a new Parkinson’s disease drug when the fire alarm sounded at the UAMS Translational Research Institute’s (TRI) Clinical Trials Innovation Unit on the fifth floor of the Jackson T. Stephens Spine and Neurosciences Institute building….

May 4, 2017

UAMS Synthetic ‘Marijuana’ Researcher Presents Findings at National Meeting

The UAMS team studying synthetic marijuana includes (l-r) principal investigator Paul Prather, Ph.D., and co-Investigators Anna Radominska-Pandya, Ph.D.; Jeffery Moran, Ph.D.; William Fantegrossi, Ph.D.; and Laura James, M.D. Not pictured is co-Investigator Keith McCain, Pharm.D.

LITTLE ROCK — Some people who use so-called synthetic marijuana, known by names such as K2 and Spice, may be unable to metabolize the drug, leading them to experience its most harmful effects, a UAMS researcher said at the recent national Experimental Biology 2017 meeting in Chicago. Anna Radominska-Pandya, Ph.D., part of a UAMS research…